A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
Active, not recruiting · NCT06907875 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT06907875 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Epicrispr Biotechnologies, Inc. | 1 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| David Geffen School of Medicine at University of California, Los Angeles | Los Angeles | United States | 1 |
| Kennedy Krieger Institute, Center for Genetic Muscle Disorders | Baltimore | United States | 1 |
| Pacific Clinical Research Network | Auckland | New Zealand | 1 |
| Rare Disease Research | Atlanta | United States | 1 |
| Royal Alfred Hospital | Sydney | Australia | 1 |
| University of Massachusetts Chan Medical School | Worcester | United States | 9 |
| Utah Program for Inherited Neuromuscular Disorders - University of Utah | Salt Lake City | United States | 1 |